High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1–DNA adduct levels in human hepatocellular carcinoma

Epigenetic changes in gene expression due to extensive CpG island methylation is now accepted as the main cause of inactivation of the p16 gene. More recently, it has been suggested that the human ras association domain family (RASSF) 1 gene, cloned from the lung tumor‐suppressor locus 3p21.3, also may be inactivated by methylation. It consists of two major alternative transcripts, RASSF1A and RASSF1C. Epigenetic inactivation of isoform A was observed in several carcinomas and tumor cell lines. In this study, promoter hypermethylation of RASSF1A and p16 was investigated in 83 hepatocellular carcinoma (HCC) tissue samples from Taiwan and in two HCC cell lines (Hep3B and HepG2). High frequencies (85% and 47%, respectively) of methylation of the CpG island promoters of RASSF1A and p16 were found in the HCC tissues. The methylation of RASSF1A also was detected in Hep3B cells but not in HepG2 cells; p16 was not methylated in either cell line. Methylation status was determined in 12 normal control liver tissues and 10 adjacent nontumor tissues. No methylation was found in normal liver control tissues for both RASSF1A and p16; methylation was detected in one of 10 and seven of 10 adjacent nontumor tissue sampless for p16 and RASSF1A, respectively, in subjects with positive tumors. These data indicate that aberrant methylation of the CpG island promoters of both genes is a frequent occurrence in hepatocarcinogenesis. The high frequency of RASSF1A methylation in adjacent tissues suggests that this may be an early event. The relationship between methylation status and clinical parameters and tumor markers, including DNA damage resulting from aflatoxin B1 (AFB1), an environmental carcinogen, and p53 status, also was analyzed. A statistically significant association was found between RASSF1A methylation status and the level of AFB1‐DNA adducts in tumor tissues. No association was found between methylation status and p53 status. These results suggest the hypothesis that exposure to environmental carcinogens may be involved in altered methylation of genes involved in cancer development. © 2002 Wiley‐Liss, Inc.

[1]  W. Doerfler,et al.  Chromosomal insertion of foreign (adenovirus type 12, plasmid, or bacteriophage lambda) DNA is associated with enhanced methylation of cellular DNA segments. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Makuuchi,et al.  Over‐expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma , 1999, International journal of cancer.

[3]  C. Ong,et al.  Aflatoxin B1-induced 8-hydroxydeoxyguanosine formation in rat hepatic DNA. , 1995, Carcinogenesis.

[4]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[5]  Keith D Robertson,et al.  DNA methylation, methyltransferases, and cancer , 2001, Oncogene.

[6]  Jack A. Taylor,et al.  Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. , 1993, Journal of the National Cancer Institute.

[7]  J. Yokota,et al.  Inactivation of p16 in Hepatocellular Carcinoma , 1998 .

[8]  S. Naylor,et al.  Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. , 1997, Advances in cancer research.

[9]  W. Doerfler.  The insertion of foreign DNA into mammalian genomes and its consequences: a concept in oncogenesis. , 1995, Advances in cancer research.

[10]  H. El‐Serag,et al.  Rising Incidence of Hepatocellular Carcinoma in the United States , 1999, Infection Control & Hospital Epidemiology.

[11]  J. Kwong,et al.  High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. , 2001, Cancer research.

[12]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[13]  C. J. Chen,et al.  p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. , 1997, Cancer research.

[14]  H. Asakura,et al.  p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. , 1999, Gastroenterology.

[15]  C. J. Chen,et al.  Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. , 1993, Biochemical and biophysical research communications.

[16]  J. Minna,et al.  Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. , 2001, Cancer research.

[17]  F. Perera,et al.  Immunological methods for monitoring human exposure to benzo[a]pyrene and aflatoxin B1. Measurement of carcinogen adducts , 1991 .

[18]  G. Pfeifer,et al.  The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas , 2001, Oncogene.

[19]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[20]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[21]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[22]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. , 2001, Cancer research.

[23]  W. Lau,et al.  Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. , 1999, Cancer research.

[24]  J. Chiu,et al.  The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors. , 1990, Oncogene.

[25]  I. Weinstein,et al.  Amplification and expression of the human cyclin D gene in esophageal cancer. , 1992, Cancer research.

[26]  H. Asakura,et al.  p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma , 1999 .

[27]  D. Sidransky,et al.  p16(MTS-1/CDKN2/INK4a) in cancer progression. , 2001, Experimental cell research.

[28]  J. Bartek,et al.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.

[29]  A. Protopopov,et al.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Hirohashi,et al.  Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis—A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma , 2000, Hepatology.

[31]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[32]  S. Hirohashi,et al.  Inactivation of p16INK4 in hepatocellular carcinoma , 1996, Hepatology.

[33]  Nita Ahuja,et al.  DNA methylation and environmental exposures in human hepatocellular carcinoma. , 2002, Journal of the National Cancer Institute.

[34]  G. Yang,et al.  Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. , 2001, Cancer research.

[35]  W. Doerfler,et al.  Insertion of Foreign DNA into an Established Mammalian Genome Can Alter the Methylation of Cellular DNA Sequences , 1999, Journal of Virology.

[36]  Chien-Jen Chen,et al.  Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.

[37]  W. Lau,et al.  High frequency of p16INK4A gene alterations in hepatocellular carcinoma , 1999, Oncogene.

[38]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[39]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[40]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.

[42]  H. Moch,et al.  Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. , 2001, Cancer research.